The Medicare Part D program attempts to “protect” from access barriers and high beneficiary out-of-pocket costs six therapeutic medication classes. These are important to many persons with disabilities. Available here are two studies, both funded by pharmaceutical companies – one on per-patient-per-month costs and the other on the impact of “utilization” management.